First Quadrant’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

First Quadrant’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-12,686	Closed	-$150K	–	1014
2017 Q3	$150K	Buy	+12,686	New	+$142K	﹤0.01%	753
2016 Q2	–	Sell	-43,200	Closed	-$472K	–	872
2016 Q1	$472K	Buy	+43,200	New	+$546K	0.01%	499
2015 Q4	–	Sell	-14,500	Closed	-$288K	–	866
2015 Q3	$288K	Buy	+14,500	New	+$332K	0.01%	514

Other funds holding SCMP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

First Quadrant's SCMP Position: Q4 2017 in Review

First Quadrant sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2017, closing a stake of 12,686 shares — an estimated $150K sold.

First Quadrant first reported a position in SCMP in Q3 2015 and held it in 3 quarters. The position peaked at $472K in Q1 2016. 188 funds tracked by Wall St. Rank hold SCMP as of Q4 2017.

First Quadrant reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
First Quadrant sold 12,686 Sucampo Pharmaceuticals, Inc. shares in Q4 2017, an estimated $150K.
First Quadrant first reported a position in Sucampo Pharmaceuticals, Inc. in Q3 2015 and held it in 3 quarters.
First Quadrant's Sucampo Pharmaceuticals, Inc. position peaked at $472K in Q1 2016.
188 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2017.

Based on First Quadrant's 13F filing for Q4 2017, filed 23 Jan 2018.